Subject(s)
Arrhythmias, Cardiac/etiology , Myocardial Ischemia/complications , Ventricular Fibrillation/etiology , Animals , Arrhythmias, Cardiac/metabolism , Arrhythmias, Cardiac/physiopathology , Fructosediphosphates/metabolism , Glucosephosphates/metabolism , Glycolysis , Phosphoenolpyruvate/metabolism , Phosphorylation , Rats , Rats, Wistar , Ventricular Fibrillation/metabolism , Ventricular Fibrillation/physiopathologyABSTRACT
Acute experiments on unconscious rats have demonstrated that fructose-1,6-diphosphate, phosphoenolpyruvate and malate of sodium produced a marked antiarrhythmic activity in acute occlusive and reperfusion arrhythmias, prevented the development of ventricular fibrillation and tachycardias, considerably reduced the duration of arrhythmia paroxysms, but they were ineffective in ventricular extrasystole.
Subject(s)
Anti-Arrhythmia Agents/therapeutic use , Arrhythmias, Cardiac/drug therapy , Citric Acid Cycle , Coronary Disease/drug therapy , Glycolysis , Myocardial Reperfusion Injury/drug therapy , Acute Disease , Animals , Arrhythmias, Cardiac/etiology , Coronary Disease/complications , Drug Evaluation, Preclinical , Female , Male , Myocardial Reperfusion Injury/complications , Rats , Rats, Wistar , Time FactorsABSTRACT
Fructose-1,6-diphosphate (150 and 50 mg/kg) and phosphoenolpyruvate (0.5 and 0.1 mg/kg) decreased the development of ventricular tachycardia, ventricular fibrillation and the intensity of ventricular extrasystoles after coronary occlusion in experimental rats. Both compounds were active as anti-fibrillation agents on reperfusion arrhythmias. Fructose-1,6-diphosphate potentiated the effect of lidocaine.
